Company / Operating Income
Regeneron Pharmaceuticals Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$3.6B
FY2025
5-year range
$2.2B / $4.0B
FY2021-FY2025
Trend
-10.3%
vs FY2024
Sector context
#6 of 204
Health Care
What the data says
Among 204 Health Care companies, Regeneron Pharmaceuticals is in the top 3% for operating income. Operating Income has fluctuated over the past 10 years, ranging from $1.3B in FY2016 to $4.0B in FY2023.
Based on SEC 10-K filings.
$3.6B in FY2025 with a 5-year CAGR of +7.1%. Top quartile in the Health Care sector.
Declined from $4.0B to $3.6B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- +7.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 204This company $3.6B Sector average $107.7M
▼
+3221.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.1%, indicating consistent growth.
- In FY2025, operating income decreased 10.3% year-over-year.
- Ranks #6 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.6B | -10.3% |
| FY2024 | $4.0B | -1.4% |
| FY2023 | $4.0B | +13.2% |
| FY2022 | $3.6B | +61.9% |
| FY2021 | $2.2B | -12.8% |
| FY2020 | $2.5B | +14.7% |
| FY2019 | $2.2B | -12.8% |
| FY2018 | $2.5B | +21.9% |
| FY2017 | $2.1B | +56.3% |
| FY2016 | $1.3B | +6.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026